Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity

Chiaki Iwamura,3 Kiyoshi Hirahara2,4,5, Masahiro Kiuchi,6 Sanae Ikeharab,7 Kazzahiko Azuma,8 Tadanaga Shimada1,9, Sachiko Kuriyama2,9, Syota Ohkib,9, Kota Kokuboa3,4,9, Yoshio Suzukio,10, Mitsuhiro Tsujiwakip,9, Terufumi Kubop,9, Tadashi Hasegawap,9, Ichiro Yoshinou,9, Motoko Y. Kimurat,2 and Takuji Suzukin2

EMERGING ISSUES: Pathological and immunological studies are important to control the COVID-19 pandemic. We found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accumulates in the pulmonary vessels, causing exudative vasculitis accompanied by the emergence of thrombospondin-1–expressing noncanonical monocytes and the formation of myosin light chain 9 (Myl9)–containing microthrombi in the lung of COVID-19 patients with fatal disease. The amount of plasma Myl9 in COVID-19 was correlated with the clinical severity, and measuring plasma Myl9 together with other markers allowed us to predict the severity of the disease more accurately. This study provides detailed insight into the pathogenesis of vasculitis and immunothrombosis, which may lead to optimal medical treatment for COVID-19.

The mortality of coronavirus disease 2019 (COVID-19) is strongly correlated with pulmonary vascular pathology accompanied by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection–triggered immune dysregulation and aberrant activation of platelets. We combined histological analyses using field emission scanning electron microscopy with energy-dispersive X-ray spectroscopy analyses of the lungs from autopsy samples and single-cell RNA sequencing of peripheral blood mononuclear cells to investigate the pathogenesis of vasculitis and immunothrombosis in COVID-19. We found that SARS-CoV-2 accumulated in the pulmonary vessels, causing exudative vasculitis accompanied by the emergence of thrombospondin-1–expressing noncanonical monocytes and the formation of myosin light chain 9 (Myl9)–containing microthrombi in the lung of COVID-19 patients with fatal disease. The amount of plasma Myl9 in COVID-19 was correlated with the clinical severity, and measuring plasma Myl9 together with other markers allowed us to predict the severity of the disease more accurately. This study provides detailed insight into the pathogenesis of vasculitis and immunothrombosis, which may lead to optimal medical treatment for COVID-19.

COVID-19 | exudative vasculitis | nonconventional monocytes | microthrombi | plasma Myl9

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus causing coronavirus disease 2019 (COVID-19) and affecting billions of people worldwide. COVID-19 patients showed a higher mortality rate during hospitalization than patients with influenza infection (1). The fatality rate due to COVID-19 was ~1 to 2%, depending on the age of the patient, the presence or absence of underlying diseases, and the location of residence (2, 3). Although vaccination is effective in preventing the onset and severity of COVID-19, globally, weekly conformation of myosin light chain 9 (Myl9)–containing microthrombi in the lungs of COVID-19 patients during COVID-19 (COVID-19) patients with fatal disease. More interestingly, we demonstrate that SARS-CoV-2–induced platelet activation causes an increase in the plasma Myl9 level, which is closely correlated with clinical severity. The measurement of plasma Myl9 with other markers allowed us to diagnose the severity of the disease more accurately, which is crucial for providing appropriate medical care for COVID-19 patients.

Significance

Elucidation of the pathology triggered by SARS-CoV-2 infection is essential to control the pandemic. We found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accumulates in the pulmonary vessels, causing exudative vasculitis accompanied by the emergence of noncanonical monocytes that specifically produce a platelet activating factor, thrombospondin-1, and the formation of myosin light chain 9 (Myl9)–containing microthrombi in the lungs of COVID-19 patients. The amount of plasma Myl9 was closely correlated with clinical severity. The measurement of plasma Myl9 with other markers allowed us to diagnose the severity of the disease more accurately, which is crucial for providing appropriate medical care for COVID-19 patients.
cases than in those who died of influenza (22). Indeed, an increased level of D-dimer, which reflects the activation of the coagulation system, is associated with a poor prognosis (23). However, the details concerning the cascade of pathological and immunological events and the critical factors involved in innate and adaptive immunity in immunosuppression accompanied by vasculitis in critical COVID-19 remain unclear.

We found that SARS-CoV-2 infection caused exudative vasculitis as well as the accumulation of SARS-CoV-2 elements in the middle smooth muscle layer of the arteries in the lungs of fatal COVID-19 cases. Single-cell RNA-sequencing (scRNA-seq) analyses revealed increased numbers of myeloid cells with biased up-regulation of platelet-activating signature, especially thrombospondin-1 (THBS-1)—expressing noncanonical monocytes. Microthrombi accompanied by the degradation of myosin light chain 9 and 12 (Myl9/12) were detected in the arteries of the lungs of fatal COVID-19 cases. The concentration of plasma Myl9 was significantly increased in COVID-19 patients. More importantly, we have found that the plasma Myl9 level reflects the clinical condition of COVID-19 patients. Plasma Myl9 will be a biomarker to predict the severity of COVID-19 and a potential therapeutic target for preventing microthrombosis and intractable vasculitis in COVID-19.

Results

Introduction to the Patient Cohort. All of the patients enrolled in this study were diagnosed with or denied to have COVID-19 based on positive and negative RT-PCR findings, respectively, and stratified according to disease severity (24, 25) (SI Appendix, Table S1). To assess the impact of SARS-CoV-2 infection on both local inflammatory sites and the systemic immune system, we analyzed five autopsy samples, including three individuals who died with COVID-19, one that died with stomach cancer, and one that died with hereditary diffuse leukoencephalopathy (cohort 1) (Table 1 and SI Appendix, Fig. S1 A, Upper), and 177 whole-blood samples, including 123 from individuals with COVID-19 (cohort 2) (SI Appendix, Fig. S1 A, Lower). Of the 123 patients with COVID-19 in cohort 2, we collected blood samples once a week from moderate or severe patients and every 3 d from critical patients, with a total of 400 samples obtained.

Regarding patients’ information, their medical conditions revealed that the patients enrolled in this study showed phenotypic characteristics of COVID-19 (Table 2). Of all patients enrolled in cohort 2, almost half of the patients (n = 60) showed moderate symptoms, while the other half (n = 63) showed more severe symptoms. The median age of the enrolled patients was 57 y. Female patients account for 33% of all patients, and the proportion of female patients was decreased in more severe groups. The numbers of patients with higher body mass index (BMI) values or complications, such as hypertension and diabetes, were increased in more severe groups. The lactate dehydrogenase (LDH), D-dimer, C-reactive protein (CRP), and ferritin levels, the neutrophil count, and the levels of plasma inflammatory cytokines, such as interleukin (IL)-6, IL-8, IP-10, and MCP-1, increased in correlation with the severity of COVID-19 (SI Appendix, Fig. S1 B). These results indicate that our cohort 2 recapitulated the findings of previous reports (3–5, 26).

Aggregated SARS-CoV-2 Particles Disrupted the Tunica Media, Resulting in Exudative Changes in the Bronchovascular Space. We first assessed the lung autopsy material from three individuals with COVID-19 to investigate the pathological impact of SARS-CoV-2 infection in the lungs (cases #1 to #3) (Table 1). Notably, case #2 suffered from mucormycosis, which has been described in several other studies, especially in India (27–29). A representative figure from a computed tomography (CT) analysis of case #2 showed pneumonia characteristic of COVID-19.

Table 1. Clinical characteristics of COVID-19 patients with autopsy

| Variable                  | Case #1 | Case #2* | Case #3 |
|---------------------------|---------|----------|---------|
| Age (y)                   | 86      | 58       | 80      |
| Sex                       | Male    | Male     | Male    |
| Comorbidity               | None    | Diabetes | Diabetes |
|                           |         | Hypertension | Hypertension |
|                           |         | Idiopathic pulmonary fibrosis | Dyslipidemia |
| Treatments                |         |          | Prostatic hyperplasia |
| Steroid                   | None    | +        | +       |
| Antivirus                 |         | +        | +       |
| Antibiotics               |         | +        | +       |
| Anticoagulant             |         |          |         |
| Hospitalization           | 3/7/21 to 3/7/21 | 11/28/20 to 12/30/20 | 3/11/20 to 03/28/20 |
| (on admission-deceased)   |         |          |         |
| PCR test result           | Positive (3/7/20), negative (not tested) | Positive (11/27/20), negative (12/1/20) | Positive (3/12/20), negative (not tested) |
| MV (d)                    | 0       | 30       | 15      |
| ECMO (d)                  | 0       | 21       | 0       |
| Complication              | None    | Mucormycosis | Renal failure |
|                           |         | Pulmonary and renal infarction | Anemia |
|                           |         | Nonocclusive mesenteric ischemia | Liver dysfunction |
| Cause of death            | Acute respiratory distress syndrome | Cerebral hemorrhage | Multiple organ failure |
|                           |         | COVID-19 pneumonia |         |

*The details about case #2 are described in a published case report (28).
(SI Appendix, Fig. S1C). Histological analyses of lung samples from all patients revealed features characteristic of diffuse alveolar damage, with hypercellular thickening of the alveolar septa, fibrosis, hyaline membrane, and extensive cellular infiltration (SI Appendix, Fig. S1D). Using immunohistochemistry, distinct immunoreactivity for the spike protein of SARS-CoV-2 was detected in the vascular wall in samples from fatal COVID-19 cases (Fig. 1 A Upper, black arrowhead) but not in control samples (Fig. 1 A Lower). On the ultrastructural level, aggregated SARS-CoV-2 particles were detected in the tunica media by field emission scanning electron microscopy (FE-SEM), by specific spike protein antibody and Cobalt labeled 3',4'-diaminobenzidine (DAB) using energy-dispersive X-ray spectroscopy (EDX) (Fig. 1B and SI Appendix, Fig. S1E). Elastin van Gieson (EVG) staining of the lung samples revealed thickening and disruption of elastic fibers in the SARS-CoV-2–infected arteries (Fig. 1 C, Upper), while thin layers of elastic fibers were found in the arteries of control samples (Fig. 1 C, Lower). Consistent with disruption of the tunica media, the tunica adventitia and bronchovascular space showed characteristic histological features of exudative inflammation with tearing and thickening of the elastic fibers in the vessel wall accompanied by dilation of the adventitia (Fig. 1 D, Left, black arrowhead) and enlargement of the lymphatics (Fig. 1 D, Left, white arrowhead). A significant increase in the dimensions of the adventitia was detected in the lungs of fatal COVID-19 cases compared with the control lungs (Fig. 1 D, Right). In contrast, the typical features of exudative vasculitis were not observed in the kidneys of cases #1 and #2 (SI Appendix, Fig. S1F). These findings revealed that the arteries in the lungs of fatal COVID-19 cases showed exudative vasculitis together with the presence of SARS-CoV-2 elements in the arterial blood vessels.

**Single-Cell Transcriptome Profiling Reveals Dysregulation of Myeloid Cells with Biased Up-Regulation of Platelet-Activating Signature in the Blood of Critical and Fatal COVID-19 Cases.** To clarify the functional states of systemic immune cells in COVID-19, we next conducted transcriptome profiling by scRNA-seq for blood samples from 21 patients (10 moderate, 6 critical, and 5 fatal cases in our cohort 2) (SI Appendix, Fig. S1A). The blood samples used for scRNA-seq were collected on admission (n = 13) or within 10 d of admission (n = 8). A total of 57,049 single-cell

| Table 2. Characteristics of the enrolled COVID-19 patients |
|-----------------------------------------------|
| Demographics and sex                        |
| Age, median (± SD)                          |
| 20–29 y old                                 |
| 30–39 y old                                 |
| 40–49 y old                                 |
| 50–59 y old                                 |
| ≥60 y old                                   |
| Female                                      |
| BMI, Average (± SD)                        |
| Complications                               |
| Hypertension                                |
| Diabetes                                    |
| Dyslipidemia                                |
| Hyperuricemia                               |
| Respiratory diseases                        |
| Duration of hospital stay, d (IQR)          |
| Medications                                 |
| Corticosteroid                              |
| Antiviral                                   |
| Antibiotic                                  |
| Anticoagulant                               |
| Tocilizumab                                 |
| Treatments                                  |
| Mechanical ventilation                      |
| ECMO                                        |
| CHDF                                        |
| Apheresis                                   |
| Nitric oxide                                |
| Prone position                              |
| Data are presented as No. (%) unless indicated otherwise. CHDF, continuous hemodiafiltration. |

https://doi.org/10.1073/pnas.2203437119
transcriptomes of peripheral blood mononuclear cells (PBMCs) were analyzed, and uniform manifold approximation and projection (UMAP) identified 8 clusters in the PBMCs of 21 COVID-19 patients (Fig. 2A and SI Appendix, Fig. S2A). Fatal COVID-19 cases showed a decreased proportion of lymphoid cell clusters, such as CD4+ T cells and B cells, in PBMCs compared with moderate COVID-19 cases, which was consistent with the laboratory tests (Fig. 2B and SI Appendix, Figs. S1B and S2B). In contrast, the proportion of myeloid cell clusters, including conventional and nonconventional monocytes, was increased in PBMCs of fatal COVID-19 cases compared with moderate COVID-19 cases (Fig. 2B and SI Appendix, Fig. S2B). A single-sample gene-set variation analysis (ssGSVA) identified the top 10 pathways accumulated in CD45+ cells of fatal...
Fig. 2. A sc RNAseq analysis revealed dysregulation of myeloid cells with biased up-regulation of neutrophil and platelet activation gene sets in the blood of COVID-19 patients. (A) UMAP projection of CD45+ cells at 57,049 single-cell transcriptomes isolated from PBMCs of 21 patients (moderate \( n = 10 \), severe \( n = 6 \), fatal \( n = 5 \)) is depicted and colored according to the 8 cellular populations. (B) Percentages of cell compositions in PBMCs for moderate, severe, and fatal COVID-19 cases are shown. (C) The bar graph shows the ssGSVA scores in pathways enriched for fatal COVID-19 cases compared with moderate COVID-19 cases. (D) ssGSVA scores of neutrophil degranulation (Left), platelet activation, signaling, and aggregation (Center), and platelet degranulation (Right) are projected on ridgeline plots. Open rectangles with dashed lines indicate higher ssGSVA scores (neutrophil degranulation: 1.1 > ssGSVA; platelet activation, signaling, and aggregation, and platelet degranulation: 1.5 > ssGSVA). (E) Immune cells gated by ssGSVA scores in D are projected on the UMAP (Upper) and bar plot showing the counts of each cell population (under panel).
COVID-19 cases, including “neutrophil degranulation” and platelet activation-related pathways, such as “plate activation, signaling and aggregation” and “platelet degranulation” (Fig. 2C). Ridge plots revealed that CD45⁺ cells from fatal COVID-19 cases showed a higher ssGSVA score for neutrophil degranulation, platelet activation, signaling and aggregation, and platelet degranulation than those from CD45⁺ cells from critical or moderate COVID-19 cases (Fig. 2D). UMAP plots drawn using the subpopulation of CD45⁺ cells with robust activation of these pathways, which were gated in the Ridge plot (Fig. 2D, red-dotted rectangles), indicated that the majority of CD45⁺ cells with high indicated ssGSVA scores were myeloid cell clusters (Fig. 2 E, Upper), specifically a subpopulation of monocytes (Fig. 2 E, Lower). Taken together, these findings indicated that circulating immune cells in critical and fatal COVID-19 cases were characterized by increased numbers of myeloid cells with biased up-regulation of platelet-activating signature.

Noncanonical Monocytes with Enhanced Expression of THBS-1 Were Accumulated in the Lungs of Fatal COVID-19. Next, we sought to identify the molecules expressed in myeloid clusters that were involved in the pathogenicity of fatal COVID-19 cases. To this end, we analyzed our scRNA-seq datasets from PBMCs of COVID-19 patients (Fig. 2A). CD14⁺ myeloid cell clusters were divided into three subpopulations of canonical monocytes, noncanonical monocytes, and conventional dendritic cells (Fig. 3A). A total of 43 genes exhibited a >1.4-fold difference in expression between canonical and noncanonical monocytes (Fig. 3B). The gene encoding Thrombospondin 1 (THBS1) was among the most highly differentially expressed genes noncanonical monocytes and is known to promote platelet aggregation (Fig. 3E). FTLL, which encodes ferritin light chain, RENT, ANXA2, S100A11, and other genes were up-regulated in fatal COVID-19 cases among neutrophil degranulation-related genes (SI Appendix, Fig. S3A). Both the UMAP plot and violin plot confirmed the enhanced expression of THBS1 in noncanonical monocytes from fatal COVID-19 cases (Fig. 3 D and E). In contrast, SRGN, which encodes Serglycin, a hematopoietic proteoglycan core protein, was expressed in a variety of types of immune cells (SI Appendix, Fig. S3 B and C). Histological analyses of the lungs from fatal COVID-19 cases in our cohort 1 revealed the infiltration of THBS1–expressing CD163⁺ noncanonical monocytes around the inflammatory vessels, but the samples from control patients showed no infiltration of such a cell population (Fig. 3F). These results indicate that the lungs from fatal COVID-19 cases were characterized by the infiltration of noncanonical monocytes, which have the potential to induce platelet activation at local inflammatory sites.

Plasma Myl9 Levels Depicted the Severity of COVID-19. Consistent with the infiltration of noncanonical monocytes with an up-regulated platelet-activating signature in the lungs of fatal COVID-19 cases, we detected the formation of microthrombi stained by phosphotungstic acid-hematoxylin (PTAH) in arteries with exudative vasculitis of the lungs of fatal COVID-19 cases in cohort 1 (SI Appendix, Fig. S4A).

Myl9, a regulatory component of myosin protein, belongs to the myosin light chain family of molecules and has high homology with Myl12a (93%) and Myl12b (93%) in humans (32). Activated platelets release Myl9, which forms thrombus-like structures in the vasculature of patients with eosinophilic rhinosinusitis, an intractable allergic disease (33). Moreover, plasma Myl9 levels in patients with Crohn’s disease were correlated with the disease severity (34). Thus, we hypothesized that vasculitis induced by SARS-CoV-2 infection-activated platelets, leading to the release of Myl9 and the generation of a net-like structure. Indeed, CD41⁺ platelets accompanied by the deposition of Myl9/12 were detected within the microthrombi in the lungs of fatal COVID-19 cases (Fig. 4A and SI Appendix, Fig. S4B). To test whether the plasma Myl9 level is correlated with the severity of COVID-19, we next examined the plasma Myl9 levels in our cohort 2 using an ELISA (SI Appendix, Fig. S1A). The concentration of Myl9 in the plasma of COVID-19 patients (n = 123) at admission to hospital was significantly higher than those in healthy controls (n = 30) (Fig. 4B, blue circles versus red circles). However, the concentration of plasma Myl9 in patients with a bacterial infection, such as sepsis, was significantly higher significantly (Fig. 4B). The receiver operating characteristics (ROC) curve of the plasma Myl9 levels revealed a high predictive value for COVID-19 patients (area under the ROC curve = 0.964, 95% confidence interval [CI] 0.933 to 0.995) (Fig. 4C). In the same patients, the plasma Myl9 levels at discharge were significantly lower than those at admission (Fig. 4D), and also lower than the maximum Myl9 values during hospitalization (SI Appendix, Fig. S4C). However, some patients with fatal disease showed higher levels of Myl9 when they died in comparison to the levels at admission (Fig. 4D).

To investigate whether the severity of COVID-19 is correlated with the plasma Myl9 levels, the patients were classified according to the disease severity of COVID-19 (SI Appendix, Table S1). Both severe and critical cases (n = 24 and n = 27, respectively) showed elevated plasma Myl9 concentrations in comparison to moderate cases, even after adjustment according to sex and age (n = 60) (Fig. 4E). Fatal cases (n = 12) exhibited the highest plasma Myl9 concentrations among the four categories of disease severity (Fig. 4E). We next examined the correlations of plasma Myl9 levels with other laboratory data (Fig. 4F and SI Appendix, Fig. S4 D–F). The plasma Myl9 levels were positively correlated with the numbers of neutrophils (r < 0.0001, r = 0.742) and white blood cells (r < 0.0001, r = 0.742) and the level of LDH (P < 0.0001, r = 0.575), IL-8 (P < 0.0001, r = 0.500), and D-dimer (P < 0.0001, r = 0.466) (Fig. 4F and SI Appendix, Fig. S4 D and E). Thus, the plasma Myl9 level of COVID-19 patients at admission are able to distinguish patients with severe, critical, and fatal disease from those with moderate disease, similarly to other blood biomarkers (SI Appendix, Fig. S4F). Plasma Myl9 levels at admission were also positively correlated with the duration of hospitalization (P < 0.0001, r = 0.484) (Fig. 4G). Furthermore, a multivariate logistic regression analysis revealed that the odds ratio of Myl9 was 1.962 (95% CI, 1.465 to 2.628), suggesting that the plasma Myl9 level was associated with a risk of requiring oxygen supplementation (score ≥ 5) at 7 d after admission (SI Appendix, Fig. S4G).

Moreover, we found that patients who received anti–IL-6 antibody treatment showed a greater reduction of plasma Myl9 in comparison to patients who did not receive anti–IL-6 antibody treatment (SI Appendix, Fig. S4H). Based on reports that autoantibodies to type I IFNs or genetic defects in type I IFN signaling can be a major risk factor underlying life-threatening disease in patients with COVID-19 (7–10), we measured the plasma anti–IFN-α2 antibody levels and found that seven cases had antibodies. The levels of plasma Myl9 at admission in
Fig. 3. Noncanonical monocytes expressing THBS-1 were accumulated in the lung of COVID-19 patients. (A) The UMAP projection of CD14+ cells from moderate, severe, and critical COVID-19 cases is depicted and colored according to the cellular populations. DC, dendritic cell. (B) The volcano plot depicts the differential gene expression of noncanonical monocytes in comparison to canonical monocytes. (C) The volcano plot depicts the differential gene expressions related to platelet degranulation, activation, signaling, and aggregation between moderate and fatal COVID-19 cases. (D) The UMAP shows the expression of THBS-1 with color intensity. (E) Violin plots show the distribution of THBS-1 in each cell population of moderate, critical, and fatal COVID-19 cases. (F) Identification of noncanonical macrophages expressing CD163, and THBS-1 in the peripheral lung tissue of the fatal COVID-19 case (case #1) and control case who died of stomach cancer. The inside of the open rectangles in the Upper panels is magnified in the Lower panels, respectively.
patients with severe, critical, and fatal disease with anti–IFN-α2 antibodies were higher than those in patients without the antibodies (Fig. 4H). In contrast, the presence of hypertension or obesity did not significantly affect the plasma Myl9 levels in COVID-19 patients with severe, critical, or fatal disease (SI Appendix, Fig. S4I). In addition, some correlation ($r = 0.294$) was found between age and the plasma Myl9 level in severely ill patients (SI Appendix, Fig. S4J).
These results indicate that the plasma Myl9 level reflects the patient clinical condition and may provide an objective diagnosis of the severity of COVID-19.

Discussion

This study presents evidence that exudative vasculitis accompanied by the accumulation of SARS-CoV-2 in the arterioles of the lungs develops in fatal COVID-19. Abnormal myeloid subsets, especially noncanonical monocytes with enhanced expression of THBS-1 are accumulated in the lungs of fatal COVID-19 cases. The plasma Myl9 level reflects the clinical condition of COVID-19 patients and may predict their disease severity.

Endothelial injury and pathological changes such as microthrombi within blood vessels, have been well described in the lungs of COVID-19 patients (35). Our histopathology analysis of lung tissue from fatal COVID-19 cases additionally identified a massive exudative inflammation in the pulmonary interstitium in COVID-19 patients. Indeed, the arterioles of the lungs of all fatal COVID-19 cases had ruptured and thickened elastic fibers accompanied by dilated adventitia, which are characteristic histological changes of exudative vasculitis. However, the typical features of exudative vasculitis were not detected in the kidneys. Additional studies with a large number of autopsy cases are required to determine whether the vasculitis in COVID-19 patients is local or systemic. Ultrastructural analyses using FE-SEM with EDX showed the aggregation of SARS-CoV-2 particles in the tunica media and destruction of the tunica media of lung vessels. Destruction of the smooth muscle layer may then cause leakage of intravascular plasma into the interstitial space and COVID-19 pneumonia with severe respiratory dysfunction. Furthermore, leaking platelets from the injured vessels are likely activated by collagen in the outer membrane of blood vessels, which causes the elevation of plasma Myl9 in COVID-19 patients.

Increased evidence has shown that COVID-19 mortality is strongly correlated with the pulmonary vascular pathology, such as immunothrombosis and vasculitis (20, 36). Consistent with previous reports, we also detected microthrombi in the arteries with exudative vasculitis in the lungs of fatal COVID-19 cases. Early reports on the pathology of COVID-19 suggested that direct SARS-CoV-2 infection of the vascular endothelium might induce vascular injury and thrombosis (37, 38). However, the direct viral infection of the vascular endothelium has been controversial in light of several experimental results, including the low expression of angiotensin converting enzyme-2 (ACE-2) on the membrane of blood vessels, which causes the elevation of plasma Myl9 in COVID-19 patients.

The pathogenic roles of neutrophil activation and neutrophil-derived extracellular traps (NETs) in the immunothrombosis in COVID-19 patients have been elucidated (41–44). SARS-CoV-2 directly stimulates neutrophils to release NETs in an ACE-2–dependent manner (41). NETs are involved in the pathogenesis of immune thrombosis in various organs, such as the lung and the heart, in COVID-19 patients (42, 43). In fact, scRNA-seq of PBMCs from COVID-19 in our cohort 2 showed the up-regulation of the neutrophil degranulation pathway in fatal COVID-19 cases (Fig. 2 C and D and SI Appendix, Fig. S3A). The neutrophil degranulation-related genes that were up-regulated in COVID-19 patients with fatal disease included RETN and S100A11, which are reported as characteristic molecules of severe disease (SI Appendix, Fig. S3A) (45, 46).

Therefore, excessive neutrophil activation in COVID-19 patients with severe disease may be involved in the formation of microthrombi as well as NETs. Furthermore, our scRNA-seq datasets revealed the appearance of dysregulated myeloid cells with biased up-regulation of platelet-activating signature in critical and fatal COVID-19 cases. We identified a unique subpopulation of monocytes that specifically expressed THBS-1, which is a homotrimeric multidomain glycoprotein controlling platelet-endothelial cell interactions and supporting platelet adhesion (48). THBS-1 also contributes to von Willebrand factor-dependent thrombus formation (49).

The neutrophil activation was specifically up-regulated in the lungs of fatal COVID-19 cases but not in the lungs of fatal influenza A cases (38). Plasma THBS-1 levels were reported to be significantly elevated in COVID-19 patients compared with healthy controls (50). Indeed, we found that noncanonical monocytes with a high expression of THBS-1 specifically appeared in the PBMCs of fatal COVID-19 cases in our cohort 2. Furthermore, THBS-1-expressing CD163* monocytes had infiltrated at the local inflammatory sites in fatal COVID-19 cases in our cohort 1. Taken together, these present and previous findings indicate that THBS-1 is involved in the microthrombus formation in COVID-19.

Myl9, which is a regulatory component of myosin protein and belongs to the myosin light chain family of molecules, is a functional ligand of CD69 that is highly expressed by activated leukocytes (32, 33). In the inflamed lung, activated platelets release Myl9/12, which forms the net-like structure inside of the vessel, where activated leukocytes can migrate to the local inflammatory site via CD69-Myl9 binding, thereby causing the exacerbation of inflammation (33). Importantly, treatment with either anti-CD69 or anti-Myl9/12 antibodies ameliorates airway inflammation or inflammatory bowel disease by inhibiting the infiltration of CD69*–activated immune cells into the inflammatory tissues, suggesting that Myl9 is a therapeutic target in inflammatory diseases (33, 34).

In the case of SARS-CoV-2 infection, we detected Myl9/12-expressing platelets within the microthrombi in the arteries of the lungs from fatal COVID-19 cases. A prospective study using COVID-19 plasma in our cohort 2 revealed a significant correlation between the plasma Myl9 level and the severity of COVID-19 (Fig. 4E). In addition, the Myl9 level at admission was correlated with the duration of hospitalization and the risk of requiring oxygen supplementation at 7 d after administration (Fig. 4G and SI Appendix, Fig. S4G). Thus, plasma Myl9 can be a useful biomarker to predict the future severity of COVID-19, and the measurement of Myl9 may allow us to detect patients with a high risk of becoming critically ill.

PNAS 2022 Vol. 119 No. 33 e2203437119 https://doi.org/10.1073/pnas.2203437119 9 of 11
of plasma Myl9 (SI Appendix, Fig. S4H), which indicates the clinical utility of plasma Myl9 for determining the efficacy of antiinflammatory treatments. We also found that patients who had anti–IFN-α2 autoantibody showed higher levels of plasma Myl9 compared with patients without anti–IFN-α2 autoantibody (Fig. 4H). However, further study will be needed to determine whether the anti–IFN-α2 has neutralizing activity. Furthermore, we did not test for autoantibodies against IFN-β or IFN-γ.

After SARS-CoV-2 infection, the Myl9 level may increase earlier than other blood markers. For example, we and others showed that D-dimer, a useful biomarker for the assessment of coagulation status, is important to evaluate the severity of COVID-19 (51). An increase of D-dimer indicates the presence of thrombi that were already formed in the blood vessels because it is a degradation product after fibrin formation (52). In contrast, Myl9 is released from platelets into the blood stream immediately after the activation (33). Therefore, measurement of plasma Myl9 levels may allow us to detect the early stage of thrombus formation. Furthermore, the level of Myl9 is specifically associated with hyperactivation of platelets. Other biomarkers, including CRP, are elevated in patients with various types of inflammation, including bacterial infection and sterile inflammation (Fig. 4B). Indeed, an increase in plasma Myl9 levels was not detected in patients with bacterial infections, such as sepsis, or patients with surgical invasion (Fig. 4B). These results indicate that the local activation of platelets in the lung causes Myl9 release, resulting in high concentrations of systemic Myl9 in the plasma of COVID-19 patients, but the local activation of platelets may not be induced in patients with bacterial infection or surgical invasion. Taken together, our findings suggest that plasma Myl9 may be a useful biomarker that has the potential to identify the severity of COVID-19 at the initial assessment in the hospital, leading to the provision of optimal medical treatments to patients with high plasma Myl9 levels. Considering that the increase of plasma Myl9 suggests the presence of vasculitis in the body, it may be possible to diagnose other types of vasculitis, such as multisystem inflammatory syndrome in children (MIS-C), which causes Kawasaki disease-like vasculitis in pediatric patients (53). Furthermore, accumulating Myl9 in the arteries in the lung may be a novel therapeutic target for COVID-19 to prevent the infiltration of activated inflammatory leukocytes into the local inflamed tissue.

In summary, we found that SARS-CoV-2 infection caused exudative vasculitis accompanied by SARS-CoV-2 elements in the blood vessels in the lung of COVID-19 patients with fatal disease. The accumulation of THBS-1–expressing noncanonical monocytes around the affected vessels may contribute to the formation of Myl9-containing microthrombi by promoting platelet aggregation. Platelet activation by vascular injury or THBS-1 may result in increased plasma Myl9 levels in COVID-19 patients (SI Appendix, Fig. S5). We found that the plasma Myl9 level reflects the clinical condition of COVID-19 patients. Thus, plasma Myl9 will be a biomarker to predict the severity of COVID-19, and a potential therapeutic target for preventing microthrombosis and intractable vasculitis in COVID-19.

Materials and Methods

Study Participants. From late July 2020 to March 2021, a total of 123 patients who were confirmed by RT-PCR to have been infected with SARS-CoV-2 were included in the study. The inclusion criteria were age over 20 y old, with no specific exclusion criteria aside from the age. Blood samples were obtained from healthy subjects (n = 30), sepsis patients (n = 9), or heart surgery patients (n = 15) as control groups for COVID-19. We retrospectively evaluated and analyzed the detailed medical history, physical examination findings, and hematological and biochemical evaluation results obtained from those patients. Blood samples were collected using EDTA-2Na blood collection tubes once every week for moderate cases or two to three times per week for severe or critical cases.

These studies were approved by the ethics committee of the Chiba University Hospital (HS2002005-01) and the ethics committee of Graduate School of Medicine, Chiba University (#959). The autopsy samples were collected under a protocol approved by the ethics committee of Graduate School of Medicine, Chiba University (M10040). Written informed consent was provided by each participant or their family before the study.

Clinical Classifications and Complication Definitions. Patients were classified for COVID-19 severity by physicians according to the clinical status described in the WHO R&D Blueprint, novel Coronavirus, COVID-19 therapeutic trial synopsis (2020) (54) (Table 1). We followed the previous reports for the severity scoring system and the severity classification (24, 25). In brief, the classifications of COVID-19 by clinical status are as follows: Moderate cases, who are patients not requiring oxygen supplementation and medical care (score 3), and patients not requiring oxygen supplementation, but requiring medical care (score 4); severe cases, who are patients requiring low-flow oxygen supplementation (score 5); and critical cases, who are patients requiring high-flow oxygen devices (score 6), and patients admitted to the intensive-care unit and requiring a mechanical ventilator or extracorporeal membrane oxygenation (score 7).

Detailed descriptions of all materials and methods are provided in SI Appendix, SI Materials and Methods.

Data Availability. All study data are included in the article and SI Appendix. Additional data is available at the Gene Expression Omnibus at accession number GSE208337 (55).

ACKNOWLEDGMENTS. We thank Takashi Yoshida (Juntendo University Faculty of Medicine and Graduate School of Medicine), Yoshihumi Suzuki (Juntendo University Faculty of Medicine and Graduate School of Medicine), Ryogo Ema (Eastern Chiba Medical Center), and Rintaro Nishimura (Eastern Chiba Medical Center) for their support in performing sample acquisition; Toshinori Masuda and Haruna Eisui for managing this clinical study; Mr. Shintaro Hishiyama (BRUKER) for technical assistance on energy-dispersive X-ray spectroscopy analysis; Ms. Mika Hashimoto (Advanced Institute of Science and Technology) for technical assistance on histological analysis using immunofluorescence detection; and Damon Tumes for his careful reading and valuable suggestions. This work was supported by grants from the following: the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (Japan) Grants-in-Aid for Scientific Research (S) JP19H05650, (B) 20H03685, (C) 19K16683, 20K08769, 22K15485, and 22K15484, Transformative Research Areas (B) JP21H05120 and JP21H05121; the Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from the Japan Agency for Medical Research and Development (AMED) (JP21ek0410060 and JP21ek0410002); the Program to Develop Countermeasure Technologies against Viral and Other Infectious Diseases, AMED (JP20hei0622037); AMED–Programs for Medical Intervention (JP20gm6110005); AMED–Core Research for Evolutionary Science and Technology (JP21gm1210003); AMED–Advanced Measurement and Analysis Systems project (JP19hm0102026H001), the Japan Science and Technology Agency (JST) Fusion Oriented Research for disruptive Science and Technology (FOREST) Project (JPMJFR200R); JST–Moonshot R&D (JPMJMS2005), and by the Mochida Memorial Foundation for Medical and Pharmaceutical Research; the MSD Life Science Foundation; Kowa Life Science Foundation; and the Takeda Science Foundation.

Author affiliations: *Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; †Department of Pathology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; ‡Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; §Clinical Research Center, Chiba University Hospital, Chiba 260-8677, Japan; ¶Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8431, Japan; #Department of Respiratory Medicine, Funabashi Central Hospital, Chiba 273-8556, Japan; &Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; ††Department of Pathology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; ‡‡Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; §§Clinical Research Center, Chiba University Hospital, Chiba 260-8677, Japan; ¶¶Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8431, Japan.
Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba 286-0041, Japan; Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan; COVID-19 Vaccine Center, Chiba University Hospital, Chiba 260-8677, Japan; Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Department of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Department of Biochemistry, Nippon Medical School, Tokyo, Japan; Department of Molecular Research, Institute of Pathology, National Institute of Advanced Industrial Science and Technology, Tsukuba 305-8565, Japan; Department of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Department for Research on Evolutionary Science and Technology, Japan Agency for Medical Research and Development, Chiba 260-8670, Japan

Author contributions: C.J., K.H., M.K., and T. Nakayama designed research; C.I., M.K., T. Hasegawa, C. Ishikawa, K. Tsuji, T. Nakayama, and K.H. performed research; S. Kaneda, S.S., M. Tobiume, Y. Suzuki, M. Tsujiwaki, T. K., R. Hase, Y.K., N.K., T.T., S. Kanesada, S.S., M. Tobiume, Y. Suzuki, M. Tsujiwaki, T. K., Hasegawa, N. Nakase, O.N., Takahashi, K., Y. Iizuka, H. Nakajima, T. Suzuki, T.-a., H. Ichihara, and K.Y. performed research; C.I., K.H., Y. Inaba, S. Shikyo, M.H.Y., H.Y., I. Ikebara, and T. Nakayama analyzed data; and C.I., K.H., and T. Nakayama wrote the paper.

The authors declare no competing interest.